Dennis Bhatt

Dennis Bhatt leads degrader medicinal chemistry efforts at Pfizer, developing strategies to optimize the drug-like properties of PROTAC molecules including oral bioavailability, metabolic stability, and tissue distribution. His work addresses the key challenge of converting large bifunctional PROTAC molecules into orally bioavailable drugs that achieve therapeutic concentrations at tumor sites. He has contributed to establishing medicinal chemistry design principles for degrader molecules that balance ternary complex formation with pharmaceutical properties.